EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions

Giulia Alagna iD, Paolo Mazzone, Marco Contarini, Giuseppe Andò iD

Journal of Cardiovascular Development and Disease · 09.04.2023 · 10 (4) · 163

DOI: 10.3390/jcdd10040163 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 09.04.2023. Verfasst von Giulia Alagna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of the platelet P2Y12 receptor for ADP, remains among the most investigated treatments in cardiovascular medicine. While a substantial amount of research initially stemmed from the observations of late and very late stent thrombosis events in the first-generation drug-eluting stent (DES) era, DAPT has been recently transitioning from a purely stent-related to a more systemic secondary prevention strategy. Oral and parenteral platelet P2Y12 inhibitors are currently available for clinical use. The latter have been shown to be extremely suitable in drug-naïve patients with acute coronary syndrome (ACS), mainly because oral P2Y12 inhibitors are associated with delayed efficacy in patients with STEMI and because pre-treatment with P2Y12 inhibitors is discouraged in NSTE-ACS, and in patients with recent DES implantation and in need of urgent cardiac and non-cardiac surgery. More definitive evidence is needed, however, about optimal switching strategies between parenteral and oral P2Y12 inhibitors and about newer potent subcutaneous agents that are being developed for the pre-hospital setting.

Schlagwörter

Stichwörter der Autor:innen

P2Y12 inhibitorsacute coronary syndromecangrelorclopidogreldual antiplatelet therapyprasugrelselatogrelticagrelorzalunfiban

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.
  • Cardiology Unit, "Umberto I" Hospital, 96100 Siracusa, Italy.

ORCID-Profile: Giulia Alagna, Giuseppe Andò

Zitieren

APA

Alagna, G., Mazzone, P., Contarini, M., & Andò, G. (2023). Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions. Journal of Cardiovascular Development and Disease, 10(4), 163. https://doi.org/10.3390/jcdd10040163

Vancouver

Alagna G, Mazzone P, Contarini M, Andò G. Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions. Journal of Cardiovascular Development and Disease. 2023;10(4):163. doi:10.3390/jcdd10040163

BibTeX
@article{Alagna2023,
  author = {Alagna, Giulia and Mazzone, Paolo and Contarini, Marco and Andò, Giuseppe},
  title = {Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2023},
  volume = {10},
  number = {4},
  pages = {163},
  doi = {10.3390/jcdd10040163}
}
Kostenlos starten →